PT  - JOURNAL ARTICLE
AU  - Iwaya, T.
AU  - Endo, F.
AU  - Yaegashi, M.
AU  - Sasaki, N.
AU  - Fujisawa, R.
AU  - Hiraki, H.
AU  - Akiyama, Y.
AU  - Sasaki, A.
AU  - Suzuki, Y.
AU  - Masuda, M.
AU  - Yamada, T.
AU  - Takahashi, F.
AU  - Tokino, T.
AU  - Sasaki, Y.
AU  - Nishizuka, S.S.
TI  - Frequent tumor burden monitoring of esophageal squamous cell carcinoma with circulating tumor DNA using individually designed digital PCR
AID  - 10.1101/2020.05.01.20087106
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.01.20087106
4099  - http://medrxiv.org/content/early/2020/05/06/2020.05.01.20087106.short
4100  - http://medrxiv.org/content/early/2020/05/06/2020.05.01.20087106.full
AB  - Background Circulating tumor DNA (ctDNA) test has not yet been an established tool for monitoring cancer. Sensitive, yet affordable methods should allow frequent ctDNA monitoring that can assist in clinical management.Patients and Methods This prospective observational study was conducted in a total of 36 patients with Stage I to IV esophageal squamous cell cancer (ESCC) were enrolled between September 1, 2015 and February 28, 2018. We investigated whether frequent ctDNA monitoring during treatment followed by routine surveillance by digital PCR (dPCR) using tumor-specific mutations offers clinical validity in daily practice for ESCC patients.Results Mutation screening of tumors from analyzable 35 patients using a specifically-designed "SCC panel" revealed 221 mutations with variant allele frequency (VAF) >2%. VAF of ctDNA was informative in 34 patients surveillance by dPCR using 58 mutations (1-3 per patient). A total of 569 plasma samples at 332 time points for ctDNA testing were evaluated. In pretreatment plasma, the average VAF was higher in advanced stages than earlier stages (P < .0001); tumor volume was also higher for higher VAF (r = 0.71). The ctDNA-positive rate in the pretreatment plasma of stage II or higher was 85.2% (23/27) whereas 85.7% (6/7) stage I were below the detection limit. Ninety-one % (10/11) patients whose ctDNA increased during chemotherapy showed disease progression. Among patients who recurred, ctDNA elevated with a median lead time of 149 days to the imaging diagnosis. Patients with decreased ctDNA within 3 months of initial treatment (n = 10) showed significantly better outcomes than did patients with ctDNA-positive (n = 11; P < .0001, HR 0.10, 95% CI, 0.03-0.30).Conclusions Our results indicate that frequent tumor burden monitoring using a small number of tumor-specific ctDNAs by dPCR enables prediction of relapse and chemotherapeutic efficacy, as well as relapse-free corroboration in management of ESCC patients.Competing Interest StatementDr. Iwaya received grant/research support from Nippon Kayaku, Chugai Pharmaceutical, and Daiichi Sankyo. Dr. Nishizuka received grant/research support form Array Jet, Taiho Pharmaceuticals, Boehringer-Ingelheim, Chugai Pharmaceutical, and Geninus. Dr. Nishizuka is an advisor/board member of CLEA Japan. Drs. Iwaya and Nishizuka hold a patent that might benefit from this publication (JP6544783). Dr. Suzuki received grant support from The Uehara Memorial Foundation and Takeda Science Foundation.Clinical TrialUMIN000038724Funding StatementThis work was supported by Keiryokai Collaborative Research Grant [#131, #136] and a Grant-in-Aid for Scientific Research KAKENHI [JP16H01578, JP16K19951, JP16K19952, JP17K10605, 19K09224, and JP16H06279].Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.